# JFK Communications

> JFK Communications is a privately held, founder-led public relations agency specializing in life sciences, healthcare, and medical technology. Founded in Princeton in 2004 by John F. Kouten and David Avitabile, it sells experienced counsel and execution across product launches, clinical-data communications, media relations, patient advocacy, issues management, media training, and digital strategy. Its disclosed work spans oncology, diagnostics, radiopharmaceuticals, biotechnology, and medical devices for clients including Caris Life Sciences, GE Healthcare Medical Diagnostics, Novartis Oncology, Teva Oncology, Prometheus Laboratories, and Taiho Oncology.

- **Founded:** 2004
- **Headquarters:** St. Augustine, United States
- **Founders:** John F. Kouten (Co-founder and CEO), David Avitabile (Co-founder and former president)
- **Products:** Product public relations, Media relations, Data and regulatory communications, Patient advocacy relations, Media training and issues management
- **Notable:** Built and sustained a specialist life-science communications firm founded in 2004., Won disclosed global or product agency-of-record assignments for GE Healthcare Medical Diagnostics, Caris Life Sciences, Prometheus Laboratories, and major oncology brands., Supported launches and pre-launch programs across oncology, diagnostics, radiopharmaceuticals, and medical devices.

## Products & services

- **Product public relations** — Launch planning, press kits, mechanism-of-action videos, testimonials, spokesperson development, trade-show support, advocacy relations, and employee engagement for pharmaceutical, diagnostic, and medical-device products.
- **Media relations** — Message development, spokesperson preparation, media monitoring, editorial-calendar analysis, expert pitching, and earned-media measurement.
- **Data and regulatory communications** — Communications planning around clinical trials, INDs, NDAs, BLAs, 510(k)s, PMAs, FDA advisory committees, approvals, withdrawals, compliance events, expanded access, and publication support.
- **Patient advocacy relations** — Patient-first education and partnerships delivered through workshops, events, blogs, physician articles, videos, and resource programs.
- **Media training and issues management** — Preparation for interviews and high-stakes scrutiny, plus counsel for product, corporate, regulatory, and reputational issues.
- **Digital, social, and inbound marketing** — Measurable content programs that repurpose technically reviewed material across web, social, lead-generation, and owned channels.

## Achievements

- Built and sustained a specialist life-science communications firm founded in 2004.
- Won disclosed global or product agency-of-record assignments for GE Healthcare Medical Diagnostics, Caris Life Sciences, Prometheus Laboratories, and major oncology brands.
- Supported launches and pre-launch programs across oncology, diagnostics, radiopharmaceuticals, and medical devices.
- Helped launch a colorectal-cancer clinical-trial matching resource for the Coalition of Cancer Cooperative Groups.
- Published the 2014 Healthcare Marketing Report and advocated measurable integration of inbound marketing with traditional healthcare PR.

## Latest updates

- **2026-08** — Published commentary on treatment progress and remaining unmet need in metastatic breast cancer.
- **2026-03** — Published an explainer on agentic AI in pharmaceutical research, development, and business operations.
- **2026-02** — Published analysis of the FDA's heightened pharmaceutical compliance enforcement.
- **2025-04** — Published a guide built from attendance at 25 ASCO annual meetings.

## Links

- Website: https://jfkhealth.com
- LinkedIn: https://www.linkedin.com/company/jfk-communications
- Twitter/X: https://twitter.com/jfkhealth
- YouTube: https://www.youtube.com/channel/UCic5rcS7c53Bx58AFg6
- Facebook: https://facebook.com/pages/JFK-Communications/107536420535

---

Profile page: https://yespress.io/jfk-communications
Published by YesPress — https://yespress.io
Last updated: 2026-09-20